OverviewSuggest Edit

GlaxoSmithKline is a science-led healthcare company. The company has three businesses that research, develop and manufacture pharmaceutical medicines, vaccines, and consumer healthcare products. GlaxoSmithKline manufactures products for major disease areas such as asthma, cancer, infections, diabetes, and mental health.
TypePublic
Founded2000
HQBrentford, GB
Websitegsk.com
Employee Ratings3.9

Latest Updates

Employees (est.) (Dec 2018)95,490(-3%)
Job Openings2,281
Revenue (FY, 2018)£30.8 B(+3%)
Share Price (May 2020)£1.7 K

Key People/Management at GlaxoSmithKline

Jonathan Symonds

Jonathan Symonds

Non-Executive Chairman
Emma Walmsley

Emma Walmsley

Chief Executive Officer
Dmytro Oliinyk

Dmytro Oliinyk

Non-Executive Director
Simon Dingemans

Simon Dingemans

Chief Financial Officer
Shakir Rahim

Shakir Rahim

Chief Executive Officer
Iain MacKay

Iain MacKay

Chief Financial Officer
Show more

GlaxoSmithKline Office Locations

GlaxoSmithKline has offices in Brentford, Tiranë, Boudouaou, Victoria and in 70 other locations
Brentford, GB (HQ)
980 Great West Rd
Tiranë, AL
Bulevardi Dëshmorët e Kombit
Victoria, AR
Carlos Casares 3690
Abbotsford, AU
level 3/436 Johnston St
Boronia, AU
1061 Mountain Hwy
Wien, AT
Gebäude I, Wagenseilgasse
Show all (88)

GlaxoSmithKline Financials and Metrics

GlaxoSmithKline Revenue

Embed Graph
View revenue for all periods
GlaxoSmithKline's revenue was reported to be £30.82 b in FY, 2018 which is a 2.1% increase from the previous period.
GBP

Revenue (Q2, 2019)

7.8b

Gross profit (Q2, 2019)

5.2b

Gross profit margin (Q2, 2019), %

66.2%

Net income (Q2, 2019)

1.1b

EBIT (Q2, 2019)

1.5b

Market capitalization (29-May-2020)

83.9b

Closing stock price (29-May-2020)

1.7k

Cash (30-Jun-2019)

4.1b

EV

113.2b
GlaxoSmithKline's current market capitalization is £83.9 b.
Annual
GBPFY, 2016FY, 2017FY, 2018

Revenue

27.9b30.2b30.8b

Revenue growth, %

17%8%2%

Cost of goods sold

9.3b10.3b10.2b

Gross profit

18.6b19.8b20.6b
Quarterly
GBPQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Revenue

7.4b7.3b7.8b7.2b7.3b8.1b7.7b7.8b

Cost of goods sold

2.5b2.6b2.7b2.4b2.3b2.6b2.7b2.6b

Gross profit

4.9b4.7b5.2b4.8b5.0b5.5b4.9b5.2b

Gross profit Margin, %

66%64%66%67%68%67%64%66%
Annual
GBPFY, 2016FY, 2017FY, 2018

Cash

4.9b3.8b3.9b

Accounts Receivable

6.0b6.0b6.4b

Inventories

5.1b5.6b5.5b

Current Assets

16.7b15.9b16.9b
Quarterly
GBPQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Cash

4.5b4.0b4.7b4.0b4.0b3.8b4.1b4.1b

Accounts Receivable

6.2b6.2b6.5b6.1b6.6b7.3b6.6b6.9b

Inventories

5.4b5.7b5.7b5.7b5.9b5.8b5.7b6.0b

Current Assets

16.8b16.4b17.7b16.4b17.0b17.4b17.5b18.2b
Annual
GBPFY, 2016FY, 2017FY, 2018

Net Income

1.1b2.2b4.0b

Depreciation and Amortization

1.9b3.0b1.8b

Cash From Operating Activities

6.5b6.9b8.4b

Purchases of PP&E

(1.5b)(1.5b)(1.3b)
Quarterly
GBPQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Net Income

1.2b1.1b2.5b759.0m1.2b1.5b985.0m2.0b

Depreciation and Amortization

326.0m1.4b2.1b478.0m673.0m1.2b1.2b2.0b

Cash From Operating Activities

1.1b2.2b4.0b863.0m2.2b4.3b663.0m2.1b

Purchases of PP&E

(260.0m)(639.0m)(1.0b)(258.0m)(541.0m)(842.0m)(222.0m)(501.0m)
GBPY, 2019

EV/EBIT

76.3 x

EV/CFO

55.2 x

EV/FCF

70.1 x

Debt/Equity

11.3 x

Debt/Assets

0.5 x

Financial Leverage

21.4 x
Show all financial metrics

GlaxoSmithKline Operating Metrics

FY, 2016FY, 2017FY, 2018

Volume of Medicines Produced

2 b1.90 b2.30 b

Vaccines

833 m798 m770 m

Consumer Healthcare Products Produced

5 b6.20 b3.80 b

Vaccine Doses Delivered per Day

2 m2 m2 m
Show all operating metrics

GlaxoSmithKline Acquisitions / Subsidiaries

Company NameDateDeal Size
TESARODecember 04, 2018$5.10 b
NovartisMarch 27, 2018$13 b
GlycoVaxynFebruary 11, 2015$190 m
Okairos AGMay 29, 2013$325 m
Human Genome SciencesAugust 03, 2012$3 b
CellZomeMay 15, 2012£61 m
MaxiNutritionDecember 13, 2010£162 m
Nanjing MeiRui Pharma Co., Ltd.December 07, 2010$70 m
Laboratorios PhoenixJune 09, 2010$253 m
NovaMin TechnologyMay 24, 2010$135 m
Show more

GlaxoSmithKline Revenue Breakdown

Embed Graph

GlaxoSmithKline revenue breakdown by business segment: 24.8% from Consumer Healthcare, 19.1% from Vaccines and 56.0% from Global Pharmaceuticals

GlaxoSmithKline revenue breakdown by geographic segment: 25.9% from Europe, 35.3% from International and 38.9% from US

Human Capital Metrics

Source: www.gsk.com
GlaxoSmithKline's employees are reported to be approximately 45% female and 55% male.
Embed Graph
Show all human capital metrics

GlaxoSmithKline Online and Social Media Presence

Embed Graph

GlaxoSmithKline Blogs

FDA approves Zejula (niraparib) as the only once-daily PARP inhibitor in first-line monotherapy maintenance treatment for women with platinum-responsive advanced ovarian cancer regardless of biomarker status

Zejula is the only oral monotherapy available as first-line maintenance treatment for women regardless of BRCA mutational status

GSK delivers strong Q1: sales £9.1 billion +19% AER, +19% CER (Proforma +10% CER*)

GSK delivers strong Q1: sales £9.1 billion +19% AER, +19% CER (Proforma +10% CER*)

GSK presents new data from the GARNET study demonstrating potential of dostarlimab to treat a subset of women with recurrent or advanced endometrial cancer

Data accepted as a late-breaking abstract and presented as a webinar as part of the Society of Gynecologic Oncology 2020 virtual congress

GSK and Vir Biotechnology enter collaboration to find coronavirus solutions

Companies will combine their unique scientific and technical expertise to combat COVID-19 and potential future coronavirus outbreaks.

Nucala (mepolizumab) is the first anti-IL5 biologic to report positive phase 3 results in patients with nasal polyps

Pivotal data support regulatory filing for additional eosinophil-driven disease

GSK completes divestment of Horlicks and other Consumer Healthcare nutrition products in India and certain other markets

GSK today announced the completion of its divestment of Horlicks and other Consumer Healthcare nutrition products in India to Unilever.
Show more

GlaxoSmithKline Frequently Asked Questions

  • When was GlaxoSmithKline founded?

    GlaxoSmithKline was founded in 2000.

  • Who are GlaxoSmithKline key executives?

    GlaxoSmithKline's key executives are Jonathan Symonds, Emma Walmsley and Dmytro Oliinyk.

  • How many employees does GlaxoSmithKline have?

    GlaxoSmithKline has 95,490 employees.

  • What is GlaxoSmithKline revenue?

    Latest GlaxoSmithKline annual revenue is £30.8 b.

  • What is GlaxoSmithKline revenue per employee?

    Latest GlaxoSmithKline revenue per employee is £322.8 k.

  • Who are GlaxoSmithKline competitors?

    Competitors of GlaxoSmithKline include Bayer, Novartis and Merck.

  • Where is GlaxoSmithKline headquarters?

    GlaxoSmithKline headquarters is located at 980 Great West Rd, Brentford.

  • Where are GlaxoSmithKline offices?

    GlaxoSmithKline has offices in Brentford, Tiranë, Boudouaou, Victoria and in 70 other locations.

  • How many offices does GlaxoSmithKline have?

    GlaxoSmithKline has 88 offices.